$ATOS Read the 8k again..."The FDA has communicated to Atossa that the IND requires the following additional information: (i) certain additional stability data concerning the Drug Product (studies supporting the Drug Product stability are ongoing) and (ii) non-significant revisions to the Neoadjuvant Study protocol and informed consent form. Atossa plans to complete the required ongoing studies and submit the information required by the FDA by the end of the third quarter 2022 and to initiate enrollment into the Neoadjuvant Study, on schedule, in the fourth quarter 2022." If you had ongoing stability studies, why submit in the first place? To test the waters? To fulfill timeline goals?
4
8
8 Likes